{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:02Z","timestamp":1789603802056,"version":"build-2803163510"},"reference-count":28,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej19-0163","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T22:18:15Z","timestamp":1561414695000},"page":"581-586","source":"Crossref","is-referenced-by-count":99,"title":["Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society"],"prefix":"10.1507","volume":"66","author":[{"given":"Hiroshi","family":"Arima","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya 466-8560, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Inaba","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ariyasu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (I), Osaka Medical College, Takatsuki 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158\u2013168.","DOI":"10.1056\/NEJMra1703481"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, et al. (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40: 17\u201365.","DOI":"10.1210\/er.2018-00006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714\u20131768.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, et al. (2018) Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7: G1\u2013G7.","DOI":"10.1530\/EC-18-0068"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6 Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, et al. (2016) Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186: 3225\u20133235.","DOI":"10.1016\/j.ajpath.2016.08.020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7 Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13: 211.","DOI":"10.1186\/s12916-015-0455-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8 Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195\u2013207.","DOI":"10.1038\/nrendo.2016.205"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9 Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, et al. (2017) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4: 173\u2013182.","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10 Gonzalez-Rodriguez E, Rodriguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804\u2013816.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24: T331\u2013T347.","DOI":"10.1530\/ERC-17-0358"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12 Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, et al. (2016) Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J 63: 905\u2013912.","DOI":"10.1507\/endocrj.EJ16-0161"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13 Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T (2017) Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]. Endocr J 64: 235\u2013236.","DOI":"10.1507\/endocrj.EJ16-0596"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14 Kanie K, Iguchi G, Bando H, Fujita Y, Odake Y, et al. (2018) Two cases of atezolizumab-induced hypophysitis. J Endocr Soc 2: 91\u201395.","DOI":"10.1210\/js.2017-00414"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15 Ohara N, Ohashi K, Fujisaki T, Oda C, Ikeda Y, et al. (2018) Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review. Intern Med 57: 527\u2013535.","DOI":"10.2169\/internalmedicine.9074-17"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16 Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, et al. (2015) Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21: 749\u2013755.","DOI":"10.1158\/1078-0432.CCR-14-2353"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17 Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, et al. (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124: 3706\u20133714.","DOI":"10.1002\/cncr.31629"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18 Yanase T, Tajima T, Katabami T, Iwasaki Y, Tanahashi Y, et al. (2016) Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [Opinion]. Endocr J 63: 765\u2013784.","DOI":"10.1507\/endocrj.EJ16-0242"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19 Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P (2016) Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep 2016.","DOI":"10.1530\/EDM-16-0108"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Min L, Ibrahim N (2013) Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 1: e15.","DOI":"10.1016\/S2213-8587(13)70031-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21 Inaba H, Ariyasu H, Okuhira H, Yamamoto Y, Akamatsu H, et al. (2018) Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother 2: 565.","DOI":"10.24294\/ti.v2.i2.606"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22 Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, et al. (2018) Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc 2: 241\u2013251.","DOI":"10.1210\/js.2017-00432"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23 Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, et al. (2018) Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 109: 3583\u20133590.","DOI":"10.1111\/cas.13800"},{"key":"23","unstructured":"24 Win MA, Thein KZ, Qdaisat A, Yeung SJ (2017) Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med 35: 1039 e1035\u20131039 e1037."},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Umeguchi H, Takenoshita H, Inoue H, Kurihara Y, Sakaguchi C, et al. (2018) Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report. J Oncol Pract 14: 449\u2013451.","DOI":"10.1200\/JOP.18.00076"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Trinh B, Sanchez GO, Herzig P, Laubli H (2019) Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer 7: 52.","DOI":"10.1186\/s40425-019-0528-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27 Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N (2019) Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab 104: 550\u2013556.","DOI":"10.1210\/jc.2018-01151"},{"key":"27","unstructured":"28 The Japan Diabetes Society (2016) A recommendation for type 1 deiabetes mellitus in patients treated with immune checkpoint inhibitors (http:\/\/www.jds.or.jp\/modules\/important\/index.php?page=article&storyid=58) (In Japanese)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"29 Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, et al. (2019) Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10: 58\u201366.","DOI":"10.1007\/s13340-018-0362-2"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/7\/66_EJ19-0163\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T17:16:10Z","timestamp":1610039770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/7\/66_EJ19-0163\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0163","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}